Site Search
Google Search
search button

Breaking News:

Carl Bernstein Says Donald Trump Is 'Cornered' for the 'First Time in His Life'      - | -     Chris Christie Belives Prosecutors Likely Have 'Corroborating' Evidence that Trump Violated Campaign Finance Laws      - | -     Schiff Predicts Trump Could Face Time in Prison      - | -     Jared Kushner Advised Crown Prince on How to 'Weather' Khashoggi Scandal      - | -     After Comey Testifies, He Says It's Obvious Trump Obstructed Justice      - | -     GOP Congressman Invokes 'The Deep State'
Drug Giant Novartis Is Gearing Up To Release A Cheaper EpiPen Rival
Get Business & Technology Alerts

viewsViews 100
6 Dec 2018 04:35 PM EST

Drug giant Novartis' Sandoz division plans to launch an EpiPen rival in early 2019. The news, marking an end in sight for the 17-month saga that has stretched since the product, Adamis' Symjepi, was first approved by U.S. regulators. With a price tag of $250 for a two-pack, Symjepi is priced less than other products in the allergic reaction treatment market. Symjepi's price is "about 16.5% less" than Mylan's authorized generic EpiPen and a generic EpiPen product put out by Teva, Novartis said in a press release. The product is also set to launch amid an EpiPen shortage.

Post Your Comment
Excellent Very Good Good Fair Poor



Recently Posted Comments
FREE
AllMediaNY AllMediaNY AllMedaiNY